Announcement on Voluntary Disclosure of Approval for Clinical Trial Application of Type II Herpes Simplex Virus mRNA Vaccine

About this update from Changchun Bcht Biotechnology Co. Class A

Announcement on Voluntary Disclosure of Approval for Clinical Trial Application of Type II Herpes Simplex Virus mRNA VaccineThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Changchun Bcht Biotechnology Co. Class A